Dana Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.8M | Sell |
69,234
-162
| -0.2% | -$32.1K | 0.41% | 51 |
|
|
2025
Q4 | $13.1M | Sell |
69,396
-3,263
| -4% | -$627K | 0.38% | 56 |
|
|
2025
Q3 | $12.9M | Sell |
72,659
-510
| -0.7% | -$75.8K | 0.38% | 57 |
|
|
2025
Q2 | $8.32M | Sell |
73,169
-1,145
| -2% | -$122K | 0.28% | 84 |
|
|
2025
Q1 | $7.81M | Sell |
74,314
-1,915
| -3% | -$217K | 0.28% | 84 |
|
|
2024
Q4 | $8.17M | Sell |
76,229
-4,373
| -5% | -$494K | 0.27% | 84 |
|
|
2024
Q3 | $8.07M | Sell |
80,602
-9,454
| -10% | -$952K | 0.27% | 104 |
|
|
2024
Q2 | $7.59M | Buy |
90,056
+14,210
| +19% | +$1.13M | 0.26% | 107 |
|
|
2024
Q1 | $5.54M | Buy |
+75,846
| New | +$5.59M | 0.18% | 152 |
|
|
2020
Q4 | – | Sell |
-28,699
| Closed | -$1.71M | – | 312 |
|
|
2020
Q3 | $1.71M | Sell |
28,699
-1,930
| -6% | -$132K | 0.09% | 126 |
|
|
2020
Q2 | $2.14M | Sell |
30,629
-2,401
| -7% | -$152K | 0.12% | 112 |
|
|
2020
Q1 | $1.5M | Buy |
33,030
+6,460
| +24% | +$366K | 0.09% | 124 |
|
|
2019
Q4 | $1.73M | Sell |
26,570
-2,164
| -8% | -$145K | 0.08% | 156 |
|
|
2019
Q3 | $1.78M | Sell |
28,734
-267
| -0.9% | -$16.8K | 0.09% | 145 |
|
|
2019
Q2 | $2.06M | Buy |
29,001
+2,795
| +11% | +$206K | 0.1% | 142 |
|
|
2019
Q1 | $2.06M | Buy |
26,206
+6,286
| +32% | +$476K | 0.1% | 153 |
|
|
2018
Q4 | $1.69M | Buy |
19,920
+1,891
| +10% | +$202K | 0.09% | 167 |
|
|
2018
Q3 | $3.09M | Sell |
18,029
-3,140
| -15% | -$473K | 0.13% | 121 |
|
|
2018
Q2 | $2.74M | Sell |
21,169
-5,710
| -21% | -$637K | 0.12% | 127 |
|
|
2018
Q1 | $2.77M | Sell |
26,879
-2,416
| -8% | -$239K | 0.12% | 121 |
|
|
2017
Q4 | $2.5M | Sell |
29,295
-966
| -3% | -$83.7K | 0.11% | 144 |
|
|
2017
Q3 | $2.57M | Sell |
30,261
-342
| -1% | -$27.1K | 0.12% | 131 |
|
|
2017
Q2 | $2.32M | Buy |
30,603
+718
| +2% | +$50.2K | 0.11% | 159 |
|
|
2017
Q1 | $1.97M | Buy |
29,885
+553
| +2% | +$36.4K | 0.09% | 188 |
|
|
2016
Q4 | $1.86M | Buy |
29,332
+954
| +3% | +$60.2K | 0.09% | 191 |
|
|
2016
Q3 | $1.81M | Buy |
28,378
+614
| +2% | +$45.1K | 0.09% | 174 |
|
|
2016
Q2 | $2.07M | Buy |
27,764
+3,296
| +13% | +$245K | 0.09% | 165 |
|
|
2016
Q1 | $1.64M | Buy |
24,468
+21,709
| +787% | +$1.32M | 0.07% | 160 |
|
|
2015
Q4 | $1.72K | Sell |
2,759
-24,720
| -90% | -$1.53M | 0.08% | 149 |
|
|
2015
Q3 | $1.47M | Sell |
27,479
-5,852
| -18% | -$355K | 0.07% | 154 |
|
|
2015
Q2 | $2.1M | Buy |
33,331
+5,009
| +18% | +$273K | 0.1% | 131 |
|
|
2015
Q1 | $1.36M | Buy |
28,322
+340
| +1% | +$13K | 0.07% | 144 |
|
|
2014
Q4 | $929K | Buy |
27,982
+1,303
| +5% | +$42.4K | 0.04% | 197 |
|
|
2014
Q3 | $782K | Buy |
26,679
+4,894
| +22% | +$162K | 0.05% | 196 |
|
|
2014
Q2 | $847K | Buy |
21,785
+202
| +0.9% | +$8.2K | 0.05% | 194 |
|
|
2014
Q1 | $906K | Buy |
+21,583
| New | +$900K | 0.06% | 163 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Dana Investment Advisors's LGND Position: Q1 2026 in Review
Dana Investment Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 0.23% in Q1 2026, selling an estimated $32.1K and leaving 69,234 shares worth $13.8M. The position accounts for 0.41% of the portfolio, ranked #51.
Dana Investment Advisors first reported a position in LGND in Q1 2014 and has held it in 36 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Dana Investment Advisors held 69,234 shares of Ligand Pharmaceuticals worth $13.8M as of Q1 2026.
- Dana Investment Advisors sold 162 Ligand Pharmaceuticals shares in Q1 2026, an estimated $32.1K.
- Ligand Pharmaceuticals made up 0.41% of Dana Investment Advisors's portfolio in Q1 2026, its #51 holding.
- Dana Investment Advisors first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 36 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Dana Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.